167 related articles for article (PubMed ID: 36116121)
1. Unraveling the Transcriptomic Signatures of Homologous Recombination Deficiency in Ovarian Cancers.
Lee JJ; Kang HJ; Kim SS; Charton C; Kim J; Lee JK
Adv Biol (Weinh); 2022 Dec; 6(12):e2200060. PubMed ID: 36116121
[TBL] [Abstract][Full Text] [Related]
2. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
6. Structural Variants at the
Ewing A; Meynert A; Churchman M; Grimes GR; Hollis RL; Herrington CS; Rye T; Bartos C; Croy I; Ferguson M; Lennie M; McGoldrick T; McPhail N; Siddiqui N; Dowson S; Glasspool R; Mackean M; Nussey F; McDade B; Ennis D; McMahon L; Matakidou A; Dougherty B; March R; Barrett JC; McNeish IA; ; Biankin AV; Roxburgh P; Gourley C; Semple CA
Clin Cancer Res; 2021 Jun; 27(11):3201-3214. PubMed ID: 33741650
[TBL] [Abstract][Full Text] [Related]
7. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract][Full Text] [Related]
8. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types.
Shi Z; Chen B; Han X; Gu W; Liang S; Wu L
Sci Rep; 2023 Jun; 13(1):8899. PubMed ID: 37264024
[TBL] [Abstract][Full Text] [Related]
9. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
10. Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Thomas SN; Chen L; Liu Y; Höti N; Zhang H
J Proteome Res; 2017 Oct; 16(10):3704-3710. PubMed ID: 28866885
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study.
Yoshihara K; Baba T; Tokunaga H; Nishino K; Sekine M; Takamatsu S; Matsumura N; Yoshida H; Kajiyama H; Shimada M; Kagimura T; Oda K; Sasajima Y; Yaegashi N; Okamoto A; Sugiyama T; Enomoto T
Cancer Sci; 2023 Jun; 114(6):2515-2523. PubMed ID: 36747324
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
[TBL] [Abstract][Full Text] [Related]
15. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
16. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
[TBL] [Abstract][Full Text] [Related]
17. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
18. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
20. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
Kekeeva T; Andreeva Y; Tanas A; Kalinkin A; Khokhlova S; Tikhomirova T; Tyulyandina A; Popov A; Kuzmenko M; Volkonsky M; Chernorubashkina N; Saevets V; Dmitriev V; Nechushkina V; Vedrova O; Andreev S; Kutsev S; Strelnikov V
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
